We began by examining the effects of cisplatin and of 14 azolato-bridgedcomplexes (0–50 μM) on the viability of LNCaP cells,an AR-positive prostate cancer cell line (Figure 2A and Supporting Figure 1). This evidence concerns the gene AR and prostate carcinoma.